To Improve Blood Sugar Control
A new drug for diabetes, authorized in Europe by AstraZeneca is a fixed combination of saxagliptin and dapagliflozin. It is intended for treatment of type 2 diabetes in patients >18 years old. The new drug improves blood sugar control when metformin and/or sulfonylurea derivatives in combination with one of the tow components of the drug fail to provide adequate control, or when the patient already receives treatment with two agents saxagliptin and dapagliflozin simultaneously.
Data of three clinical trials in type 2 diabetes patients were submitted to the European Medicines Agency. In two studies the combination of saxagliptin and dapagliflozin with metformin provided a significant reduction of HbA1c versus placebo.
Results of additional study confirmed the data obtained.
Safety results of the fixed combination are similar to the known safety characteristics of saxagliptin and dapagliflozin.